早期非小细胞肺癌SABR国际实践模式调查:我们是否同步?
结果显示单次SABR使用率为38%,54%设定最大剂量上限,5种解剖场景共推荐57种剂量方案,约三分之二实践对至少一个解剖部位推荐BED10<100 Gy,提示全球实践差异显著。
要点
- 38%受访者使用单次SABR,54%设定Dmax上限,其中58%阈值≥130%处方剂量。
- 低收入和中等收入国家更少设定Dmax≥130%(30% vs 66%)和更少使用单次SABR(14% vs 44%)。
- 5种解剖场景共57种剂量方案,约三分之二实践对至少一个部位推荐BED10<100 Gy。
核心结论
- 全球早期非小细胞肺癌SABR实践存在显著差异,需要进一步数据指导处方实践,国际专家共识可能有助于标准化。
研究设计与样本
- 共255名放射肿瘤学家完成,各代表51个国家中的单一机构,受访者报告年治疗中位数为20例。
主要发现
- 38%参与者报告使用单次SABR,54%对最大剂量(Dmax)设上限。
- 设定Dmax上限者中58%报告阈值≥130%处方剂量,该上限随地区和国家经济状态变化。
- 低收入和中等收入国家受访者更少设定Dmax≥130%(30% vs 66%,P < .01)且更少使用单次SABR(14% vs 44%,P < .01)。
- 更高年SABR患者量与更高Dmax采纳相关(г = 0.23,P < .01)。
- 5种临床场景共推荐57种不同剂量方案;各场景最常见方案为外周54 Gy/3次、尖部/中央/贴胸壁50 Gy/5次、超中央60 Gy/8次。
关键数值与推荐
- 外周肿瘤最常见方案为54 Gy分3次。
- 尖部、中央和贴胸壁肿瘤最常见方案为50 Gy分5次。
- 超中央肿瘤最常见方案为60 Gy分8次。
- 约三分之二实践对至少一个解剖部位推荐BED10 <100 Gy。
临床怎么用
- 应了解单次SABR和Dmax上限设置在国际上差异较大,处方时需结合解剖位置和机构经验。
- 对超中央等高风险部位,国际最常见方案为60 Gy分8次,但需注意BED10可能低于100 Gy。
- 低收入和中等收入国家更少采用单次SABR和Dmax≥130%上限,资源条件可能影响技术选择。
局限性
- 调查通过邮件和社交媒体发放,可能存在选择偏倚。
- 每个机构仅一名代表回答,可能不能完全代表机构实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To generate an understanding of the similarities and variations in international practice patterns for SABR in early-stage non-small cell lung cancer. METHODS AND MATERIALS: An online survey was conducted from October to December 2023, addressing general clinical and technical considerations for lung SABR, and for 5 specific anatomic non-small cell lung cancer locations (peripheral, abutting chest wall, near brachial plexus, central, and ultracentral). Invitations to participate were extended through email and were distributed on social media. RESULTS: The survey was completed by 255 radiation oncologists, each representing a single institution across 51 countries. Respondents reported treating a median of 20 cases annually. A total of 38% of participants reported using single-fraction SABR, and 54% applied an upper limit on the maximum dose (Dmax). Among those who applied a Dmax limit, 58% reported a Dmax threshold at ≥130% of the prescription, though this limit varied by region and national economy status. Respondents from low- and middle-income countries were less likely to set a Dmax limit at ≥130% (30% vs 66%, P < .01) and less likely to use single-fraction SABR (14% vs 44%, P < .01). Higher annual SABR patient volumes were associated with higher Dmax adoption (г = 0.23, P < .01). Across the 5 clinical scenarios presented; 57 distinct dose regimens were recommended. The most common regimen in each scenario was: 54 Gy in 3 fractions for peripheral tumors, 50 Gy in 5 fractions for apical, central, and abutment of chest wall, and 60 Gy in 8 fractions for ultracentral tumors. Approximately two-thirds of practices recommend a biologically effective dose (BED10) <100 Gy for ≥1 anatomic sites. CONCLUSIONS: The findings reveal considerable variation in global SABR practice. These differences highlight the need for further data to guide prescription practices, and an international experts' consensus may be beneficial to standardize practice.
引用
- Alfaifi S, Louie AV, Siva S, et al. International Patterns of Practice for SABR for Early-Stage Non-Small Cell Lung Cancer: Are We All in Sync? Int J Radiat Oncol Biol Phys. 2025. PMID: 40311704. doi:10.1016/j.ijrobp.2025.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。